Exacerbations present a major clinical problem in many patients suffering from COPD.
INTRODUCTION
Exacerbations promote disease progression in COPD and frequent exacerbations increase both morbidity and mortality in patients suffering from the disease (Soler-Cataluna et al., 2005 ). An exacerbation is defined by clinical signs including dyspnea, increased sputum volumes, and sputum purulence (Anthonisen et al., 1987) . Approximately, half of the exacerbations are considered having an infectious origin where virus and bacteria are equally common (Sethi and Murphy, 2008) . Corticosteroids, either alone or, in some cases combined with antibiotics are in most cases sufficient to treat exacerbations per se. However, the effect from antibiotics is most pronounced in the case of sputum purulence and in severe exacerbations, speaking for a high degree of heterogeneity and important roles for noninfectious triggers of inflammation (Walters et al., 2009; Vollenweider et al., 2012) . A moderate preventive effect on the incidence of exacerbations has been demonstrated for inhaled corticosteroids in combination with long-acting beta agonists and the anticholinergic agent tiotropium (Calverley et al., 2007; Tashkin et al., 2008) . As a consequence, there has been a longstanding and unmet need for novel treatment strategies to prevent exacerbations in COPD.
Increased intracellular levels of cyclic adenosine monophosphate (cAMP) can reduce the activation of a wide range of recruited immune and resident cells in the lung.
Phosphodiesterase 4 (PDE4) is an intracellular enzyme that catalyses the hydrolysis of cAMP, thereby regulating its downstream signaling (Page and Spina, 2012) . The PDE4 family consists of four genes and more than 20 splice variants (Houslay et al., 2007) . PDE4 of the subtypes A-D are expressed to various extents in several cells that are of key importance in COPD including neutrophils, macrophages, dendritic cells, cytotoxic T cells, and airway epithelial cells (Page and Spina, 2011; Page and Spina, 2012) . The benzamide derivatives, roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl] This article has not been copyedited and formatted. The final version may differ from this version.
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J P E T # 2 2 9 6 4 1 5 benzamide) was identified as a potent and selective PDE4 inhibitor (Hatzelmann and Schudt, 2001 ). In clinical trials, roflumilast improves lung function and reduces the frequency of exacerbations in COPD patients with symptoms of chronic bronchitis and a history of frequent exacerbations Fabbri et al., 2009; Rennard et al., 2011) .
Structural and immunologic changes in the airways of patients with severe COPD increase the risk of chronic bacterial colonization, in particular by Pseudomonas aeruginosa, which in turn increases the risk of exacerbations and further decline in lung function (Wilkinson et al., 2003) . Initially, infection with P. aeruginosa is transient and lasts for a few months but as the disease progresses, the bacterial infection often become chronic and with appearance of mucoid and multiresistant strains, eradication becomes difficult (Murphy et al., 2008) . In an epidemiologic study, a three-fold increase risk of P. aeruginosa bacteremia was observed in COPD patients (Inghammar et al., 2014) .
The anti-inflammatory properties of roflumilast may impair airway host defense. In the light of P. aeruginosa being an important bacterial pathogen in severe COPD, both in stable disease and during exacerbations, this study set out to study a possible effect from roflumilast on the course of P. aeruginosa airway infection.
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METHODS

Animals
BALB/cJRj female mice (9-10 weeks old, weighing 18 to 22 g; Janvier-Labs, Le GenestSaint-Isle, France) were maintained under specific pathogen-free conditions and had free access to commercial chow and water. All mouse experiments were conducted according to the institutional guidelines and were approved of by the Malmo-Lund Animal Care Ethics
Committee (M90-15).
Inoculum preparation
Bioluminescent bacteria Pseudomonas aeruginosa (strain Xen 41, derived from the parental pleural isolate P. aeruginosa PA01; PerkinElmer, Waltham, MA) possesses a copy of the luxCDABE operon of Photorhabdus luminescens integrated at a single site on the chromosome. Bacteria were grown in Todd Hewitt Broth (TH) broth aerobically at 37°C.
Roflumilast treatment
Roflumilast (Selleckchem, Houston, TX) was suspended in 0.5% methylcellulose-2.5%
polyethylene glycol solution and sonicated to ensure a uniform suspension. Vehicle-treated control animals received an oral administration of polyethylene glycol-methylcellulose (0.2 ml), whereas the test group received an oral administration of roflumilast suspension (5 or 10 mg/kg). For the experiments measuring infection and inflammatory indices, the drug was administered 24 and 2 hours prior to inoculation of bacteria and animals were sacrificed 18 hour after inoculation.
Determination of bacterial colony forming units
This article has not been copyedited and formatted. The final version may differ from this version. In order to study bacterial dissemination to organs, spleen, kidney and lungs were harvested from euthanized animals. These organs were mechanically homogenized and serial dilutions were subsequently plated on TH agar plates overnight at 37°C in order to enumerate the colony-forming units (cfu) present in each organ.
Collection of lungs for immunohistochemistry and homogenization
Post sacrifice, the left lung lobes were perfused with Histofix (Histolab, Göteborg, Sweden), submerged in 4% buffered formaldehyde. After dehydration and paraffin embedding, 3 µm sections were generated from the tissue blocks. After rehydration and antigen retrieval, sections were incubated with goat antibodies against murine myeloperoxidase (MPO) or preimmune goat IgG (R&D Systems, Abingdon, England), followed by rinsing, and bound antibodies were detected using horseradish peroxidase-conjugated secondary rabbit anti-goat antibodies (diluted 1:2,500) and visualized using 3,3-diaminobenzidine as a chromogen.
Some sections were also used for staining with hematoxylin and eosin (H&E)
The right lung lobes were snap-frozen in liquid nitrogen and stored at -80°C until further analysis. The snap-frozen lungs were thawed and homogenized in T-PER solution (Thermo Scientific, Göteborg, Sweden) containing protease inhibitor (Pefabloc SC, Sigma-Aldrich) at a final concentration of 1 mM. Lung homogenates were centrifuged at 9,000 × g for 10 minutes at 4°C and the supernatants were collected. Total protein concentrations in the lung tissue homogenates were determined using a BCA kit (Sigma-Aldrich).
Cytokine assay
The cytokines IL-6, IL-10, MCP-1, INF-γ, and TNF-α were measured in plasma, BAL fluid (BALF), and lung tissue homogenates from mice after 18 hour post-infection with P.
RESULTS
Roflumilast impairs survival Pseudomonas aeruginosa airway infection
A model of P. aeruginosa airway infection was used to investigate whether there was a difference in survival comparing vehicle-treated and roflumilast-treated mice respectively ( Figure 1 ). Mice were pre-treated with vehicle or roflumilast at two different doses (5 and 10 mg/kg respectively), administered 24 hours and 2 hours before infection. At the time of infection, mice were subject to intranasal challenge with 2 x 10 8 cfu/ml bacteria and followed for 7 days. Mice showing predefined end-point criteria (immobilization and shaking) were euthanized. Roflumilast at both doses, significantly decreased survival, occurring on day two and three, compared with infected mice treated with vehicle. Non-infected mice treated with roflumilast (10 mg/kg) did not show decreased survival during seven days, nor did mice infected mice treated with vehicle (data not shown). To investigate whether continued treatment with roflumilast during the course of infection had any effect on the outcome, mice were given an additional dose (5 mg/kg) or vehicle 24 hours after instillation of bacteria.
Continued roflumilast treatment also resulted in decreased survival (Supplemental Figure 1 ).
Roflumilast increases bacterial load and dissemination
To investigate bacterial load in the airways and possible dissemination, quantitation by viable counts as well as in vivo imaging in real time (IVIS) using bioluminescent bacteria were used ( Figure 2 ). Mice were pre-treated with vehicle or roflumilast (at doses of 5 mg/kg and 10 mg/kg respectively, 24 hours and 2 hours before infection) followed by challenge intranasally with P. aeruginosa. After 18 hours, the mice were euthanized followed by collection of bronchoalveolar lavage fluid (BALF) and organs (lungs, spleens, and kidneys were homogenized). Part of BALF and organ homogenates were plated on agar plates to determine bacterial cfu (Figure 2A ). In BALF, a significant increased bacterial load was observed in mice pre-treated with the higher dose of roflumilast (10 mg/kg). In lung tissues, both doses of roflumilast increased the number of bacteria, while in spleens and kidneys, only the higher dose of roflumilast (10 mg/kg) significantly increased the bacterial loads.
Using the semi-quantitative IVIS to follow dissemination of bioluminescent bacteria in live mice, similar patterns were seen ( Figure 2B ). Dissemination of bacteria to the lungs and internal organs of the abdomen were most pronounced at the higher dose of roflumilast (10 mg/kg) ( Figure 2B ). This was confirmed by quantitation of bioluminescence where only the higher dose of roflumilast (10 mg/kg) showed a significant increase of bacteria ( Figure 2C ).
Roflumilast decreases the number of neutrophils in bronchoalveolar fluid
Following pretreatment (vehicle or roflumilast at 5 mg/kg and 10 mg/kg respectively) and intranasal infection with P. aeruginosa, mice were euthanized and BALF was collected ( Figure 3 ). Roflumilast-treatment at both doses caused a strong decrease in the total number of cells, comparing infected mice treated with vehicle with those of roflumilast-treated mice ( Figure 3A ). Differential counts showed that the number of neutrophils was strongly downregulated in mice treated with roflumilast at both doses ( Figure 3B ).
Neutrophils are key effector cells in host defense against bacterial infection. To investigate whether the number of neutrophils were decreased also in lung tissue, the myeloperoxidase (MPO) activity, a neutrophil granule protein, was determined in lung tissue homogenates ( Figure 3C ). Interestingly, increased MPO activity was observed in roflumilast-treated with infection. The neutrophil-recruiting chemokine CXCL1/KC was also measured in BALF, 18 hours post infection. A significant increase was found comparing infected mice treated with vehicle and roflumilast at 10 mg/kg ( Figure 3D ).
Roflumilast increases the number of neutrophils in lung tissue
To determine whether the decreased number of neutrophils in the BALF, corresponded to decreased recruitment or accumulation in the lung tissue, immunohistochemistry (IHC) was performed ( Figure 4 ). Following pretreatment (vehicle or roflumilast at 5 mg/kg and 10 mg/kg respectively) and intranasal infection with P. aeruginosa, lungs were collected, processed for immunohistochemistry followed by staining to detect myeloperoxidase (MPO)
or stained with a combination of haematoxylin and eosin (H&E) ( Figure 4A ). Morphometric quantification of MPO-staining was performed and a significant increase was seen in infected mice treated with roflumilast at 10 mg/kg compared with infected mice treated with vehicle alone ( Figure 4B ).
Effects from roflumilast on cytokine levels
Cytokines are important during airway infection and the impact on their production from roflumilast is an important read-out (Strieter et al., 2002) . Thus, the levels of the pro- ). However, one should bear in mind that in humans, roflumilast is used at a dose of 500 µg daily corresponding to 7-10 µg/kg ). Thus, the difference in dose used in this study compared to that used in humans differ two to three orders of magnitude.
Thus, the immunosuppressive effect seen in the current study is likely to be more pronounced than that in humans.
Whether roflumilast increases the bacterial burden in the lower airways or promotes invasive bacterial disease in patients suffering from COPD that are infected with P. aeruginosa remain to be investigated. Other factors may affect the outcome such as lung tissue remodeling and the altered immune status of the airways in COPD, aspects that were not taken into account in this model where healthy mice were used. The beneficial effects from roflumilast is obvious in patients with frequent exacerbations, chronic bronchitis, and severe COPD where it improves lung function and reduces the frequency of exacerbations Fabbri et al., 2009; Rennard et al., 2011) .
To the best of our knowledge, neither the prevalence of P. aeruginosa infection nor airway bacterial loads during the course of these clinical trials were followed. The survival of vehicle-treated and roflumilast-treated mice infected with bacteria (P.
aeruginosa, strain Xen 41) was monitored for 7 days (only the course during the first 96 hours is shown in the figure) . The treatment was two oral doses of roflumilast (5 and 10 mg/kg respectively) or vehicle alone, administered 24 hours and 2 hours before infection. At the time of infection, mice were subject to intranasal challenge with 50 µl of PBS containing 2 x 10 8 cfu/ml bacteria (six animals in each group). Statistically significant differences were found comparing the groups pretreated with roflumilast followed by infection with the group treated with vehicle followed by infection. Roflumilast alone (10 mg/kg) did not affect survival.
Statistical comparisons of survival curves was performed using the Mantel-Cox's test. **P≤0.01 and ***P 
